Indications
Asenapine is indicated for:
Schizophrenia in adults
Bipolar I disorder
Acute monotherapy for manic or mixed episodes in adults and pediatric patients 10 to 17 years of age
Adjunctive treatment to lithium or valproate in adults.
Maintenance monotherapy treatment in adults
Dosage And Administration
Schizophrenia: adults:
Initial dose: 5 mg sublingually, twice daily
Recommended dose: 5 mg sublingually, twice daily
Maximum dose: 10 mg sublingually, twice daily
Schizophrenia maintenance treatment in adults.
Initial dose: 5 mg sublingually, twice daily
Recommended dose: 5-10 mg sublingually, twice daily
Maximum dose: 10 mg sublingually, twice daily
Bipolar mania in adults: acute and maintenance monotherapy.
Initial dose: 5-10 mg sublingually, twice daily
Recommended dose: 5-10 mg sublingually, twice daily
Maximum dose: 10 mg sublingually, twice daily
Bipolar mania in pediatric patients (10-17 years): monotherapy.
Initial dose: 2.5 mg sublingually, twice daily
Recommended dose: 2.5-10 mg sublingually, twice daily
Maximum dose: 10 mg sublingually, twice daily
Bipolar mania in adults: as an adjunct to lithium or valproate
Initial dose: 5 mg sublingually, twice daily
Recommended dose: 5-10 mg sublingually, twice daily
Maximum dose: 10 mg sublingually, twice daily
Sublingual tablets should not be swallowed. It should be placed under the tongue and left to dissolve completely. It will dissolve in saliva within seconds. Eating and drinking should be avoided for 10 minutes after administration.
Side Effects
The most common adverse reactions to asenapine are akathisia, somnolence, oral hypoesthesia, dizziness, extrapyramidal symptoms, nausea, increased appetite, fatigue, and increased weight.
Precautions And Warnings
Caution should be exercised when asenapine is prescribed in elderly patients with dementia-related psychosis, QT prolongation, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, seizures, and the potential for cognitive and motor impairment.
Pregnancy And Lactation
May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Lactation studies have not been conducted to assess the presence of asenapine in human milk, the effects of asenapine on the breastfed infant, or the effects of asenapine on milk production.